Hims & Hers (HIMS) director Christopher Payne awarded 647 RSUs for Q1 2026 fees
Hims & Hers Health, Inc. director Christopher D. Payne was granted 647 Restricted Stock Units (RSUs) as equity compensation, replacing $14,875 in cash fees for the first quarter of 2026. This award was made under the company’s Director Compensation Policy at a grant price of $22.98 per RSU. The RSUs will vest in full on the company's next quarterly vesting date, with each RSU representing one share of Class A common stock.
Hims & Hers Health (HIMS) director awarded 957 RSUs for Q1 fees
Hims & Hers Health, Inc. director David B. Wells was granted 957 restricted stock units (RSUs) as part of his 2026 first-quarter board compensation. These RSUs were issued in lieu of $22,000 in cash fees, calculated using a grant price of $22.98 per unit. The RSUs will vest in full on the company’s next quarterly vesting date, and following this grant, Wells holds 957 RSUs directly.
Hims & Hers (NYSE: HIMS) issues $402.5M 2032 zero-coupon convertibles
Hims & Hers Health, Inc. has issued $402.5 million in 0.00% Convertible Senior Notes due 2032 through a private offering to qualified institutional buyers. These zero-coupon notes are convertible into cash, Class A common stock, or a combination, with an initial conversion price of approximately $29.53 per share. To manage potential dilution, the company also entered into capped call transactions for about $36.7 million, with an initial cap price of roughly $50.15 per share.
Hims & Hers (HIMS) CFO sells 7,950 shares after option exercise
Hims & Hers Health, Inc. (HIMS) CFO Oluyemi Okupe reported exercising stock options to acquire 7,950 shares at $5.01 per share and subsequently selling all 7,950 shares at an average price of $23.6372. These transactions were carried out under a Rule 10b5-1 trading plan adopted in May 2025. Following these trades, Okupe directly holds 262,954 shares and indirectly holds 7,853 shares through a trust.
Hims & Hers CFO Okupe sells $188k in Hims shares
Oluyemi Okupe, CFO of Hims & Hers Health, Inc. (NASDAQ:HIMS), sold approximately $188,000 worth of company Class A Common Stock on May 18, 2026, after exercising stock options. This transaction was conducted under a Rule 10b5-1 trading plan. The sale occurs while HIMS shares are down significantly, and the company recently reported an earnings miss and announced a $350 million convertible senior notes offering to fund expansion and acquisitions.
Hims & Hers (NYSE: HIMS) sells $350M zero-coupon convertible notes for expansion
Hims & Hers Health, Inc. has priced an upsized offering of $350 million in zero-coupon convertible senior notes due 2032, with an option for an additional $52.5 million. The net proceeds of approximately $338.5 million will be used for international expansion, including the proposed acquisition of Eucalyptus, and to invest in technology, fulfillment infrastructure, and AI capabilities. The company has also entered into capped call transactions to mitigate potential stock dilution, with an initial conversion price premium of 32.5% and a cap price at 125% over the last reported share price.
Hers Health, Inc. Prices Upsized $350 Million Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment
Hims & Hers Health, Inc. announced the pricing of an upsized $350 million offering of 0.00% convertible senior notes due 2032. The proceeds are intended to fund the company's international expansion strategy, including the proposed acquisition of Eucalyptus, invest in technology and fulfillment infrastructure for cost efficiencies, and scale AI capabilities to enhance consumer experience. The offering aims to preserve financial flexibility and leverage its closed-loop data ecosystem.
Hims & Hers Health, Inc. Prices Upsized $350 Million Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment
Hims & Hers Health, Inc. has priced an upsized $350 million offering of 0.00% convertible senior notes due 2032. The proceeds will fund international expansion, including the acquisition of Eucalyptus, invest in technology and fulfillment infrastructure for cost efficiencies, and enhance AI capabilities to improve the consumer experience. The offering aims to maintain financial flexibility while driving strategic growth initiatives.
Hims & Hers (HIMS) Stock Tumbles 7% Following $300M Convertible Notes Announcement
Hims & Hers (HIMS) stock dropped 7% after the company announced a $300 million convertible senior notes offering. The funds will primarily finance international expansion, including the acquisition of Australian telehealth platform Eucalyptus, and will also support technological infrastructure and AI capabilities. The convertible notes, maturing in 2032, are being sold to institutional investors, with a portion of the proceeds used for capped call arrangements to minimize shareholder dilution.
Hims & Hers (HIMS) Stock Drops 7% as $300M Debt Offering Rattles Investors
Hims & Hers (HIMS) stock dropped 7% after the company announced a $300 million offering of convertible senior notes due 2032. The proceeds will fund international expansion, including the acquisition of Australian telehealth platform Eucalyptus, and implement capped call transactions to mitigate dilution for Class A stockholders. The private offering to qualified institutional buyers aims to maintain financial flexibility and enhance technology, AI capabilities, and its data ecosystem.
Hims & Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment
Hims & Hers Health, Inc. (NYSE: HIMS) announced a proposed offering of $300 million in convertible senior notes due 2032, with an option for initial purchasers to buy an additional $45 million. The proceeds are intended to fund international expansion, including the acquisition of Eucalyptus, invest in technology and fulfillment infrastructure for cost efficiencies, and enhance AI capabilities to improve the consumer experience. The offering aims to preserve financial flexibility and leverage the company's closed-loop data ecosystem.
Hims & Hers Health, Inc. Class A Trade Ideas — HAM:82W
This article compiles various trading ideas and analyses for Hims & Hers Health, Inc. (HIMS), listed as HAM:82W on the Hamburg Stock Exchange. Analysts offer both bullish and bearish perspectives, highlighting the company's rapid revenue growth through telehealth and personalized treatments, but also noting concerns about growth deceleration, competitive pressures, and high valuation. The piece also details HIMS's strategic expansion into the Canadian market with the acquisition of Livewell, aiming to address critical public health needs, particularly around obesity, and its potential impact on long-term shareholder value.
Hims & Hers Health, Inc. Class A Trade Ideas — HAM:82W
This article compiles various trading ideas and analyses for Hims & Hers Health, Inc. (HIMS) stock from multiple contributors on TradingView. Analysts present both bullish and bearish perspectives, utilizing technical indicators like RSI, MACD, Fibonacci levels, and chart patterns such as cup & handle, symmetrical triangles, and ABCD patterns. Several contributors highlight recent news, including the termination of a collaboration with Novo Nordisk, as a significant factor influencing price movements and future outlook.
Susquehanna entities report 14,502,395 HIMS shares (HIMS)
Susquehanna entities have disclosed a beneficial ownership of 14,502,395 shares in Hims & Hers Health, Inc. (HIMS), representing 6.5% of the company's Class A common stock as of March 31, 2026. This filing, a Schedule 13G, indicates shared voting and dispositive power among four affiliated broker-dealer entities and includes significant option holdings. The disclosure highlights the collective influence these entities wield over a substantial portion of HIMS's outstanding shares.
Hims & Hers Health, Inc. Class A Common Stock (NY: HIMS
This article provides recent news headlines for Hims & Hers Health, Inc. (NYSE:HIMS), covering various dates from October 2025 to November 2025. Key topics include Q3 earnings exceeding expectations, expansion into new services like GLP-1 drugs and menopause care, stock performance influenced by analyst calls and insider activity, and market reactions to political statements regarding weight-loss drugs.
Hims & Hers Health, Inc. Class A Common Stock (NY: HIMS)
This page provides recent news headlines and financial data for Hims & Hers Health, Inc. (NYSE: HIMS). It lists numerous articles from The Motley Fool and Benzinga, focusing on earnings reports, stock performance, analyst opinions, and investment potential. The stock's current official closing price, as of May 14, 2026, is also displayed.
(HIMS) as a Liquidity Pulse for Institutional Tactics
This article analyzes Hims & Hers Health Inc. (NASDAQ: HIMS), highlighting a near-term strong sentiment despite persistent mid and long-term weakness. It identifies an exceptional short setup with a 113.4:1 risk-reward ratio targeting a 31.7% downside. The analysis also provides AI-generated trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
Hims Earnings: Soft Start to the Year as We Wait to See Full Benefits of Novo Partnership
Hims & Hers reported a soft start to the year with first-quarter revenue up 4% and adjusted EBITDA down 51%, both falling below guidance. Shares dropped 9% after the announcement. The company's long-term momentum is expected to be maintained through new specialties and regions, especially with its partnership with Novo and international expansion.
Hims & Hers (NYSE: HIMS) 2026 proxy details growth, control and pay
Hims & Hers Health, Inc. (NYSE: HIMS) released its 2026 proxy statement, detailing the upcoming annual meeting where stockholders will vote on director elections, auditor ratification, and executive compensation. The proxy highlighted strong 2025 financial performance, including 59% revenue growth to $2.35 billion and over 2.5 million subscribers. It also clarified the company's "controlled company" status due to CEO Andrew Dudum's significant voting power, while emphasizing the board's independent composition and performance-linked executive pay practices.
Hims & Hers Health effects new up to $250M stock buyback program, shares up ~2%
Hims & Hers Health (HIMS) has announced a new stock buyback program, authorizing the repurchase of up to $250 million of its outstanding common stock. This initiative replaces a previous authorization from November 2023. Following the news, shares of the company rose approximately 2%.
Hims & Hers CFO Oluyemi Okupe sells $588,615 in Hims stock By Investing.com
Hims & Hers Health, Inc.'s CFO, Oluyemi Okupe, sold 19,645 shares of Class A Common Stock for $588,615 as part of a pre-arranged trading plan. Concurrently, Mr. Okupe acquired 12,553 shares through stock option exercises for $108,530. Following these transactions, he directly holds 262,954 shares, with an additional 7,853 shares held indirectly.
Hims & Hers CFO Oluyemi Okupe sells $588,615 in Hims stock
Hims & Hers Health, Inc. CFO Oluyemi Okupe sold 19,645 shares of HIMS stock for $588,615 as part of a pre-arranged trading plan, while also acquiring 12,553 shares through option exercises. Following these transactions, Okupe directly holds 262,954 shares and indirectly holds 7,853 shares. The company has also seen recent developments related to Amazon's entry into weight management and FDA discussions on peptides, influencing analyst ratings.
Hims & Hers Health Legal Chief Sells Shares Worth Over $280000
Soleil Boughton, the Chief Legal Officer of Hims & Hers Health, Inc. (HIMS), sold 9,463 shares of the company's Class A Common Stock for over $280,000 on April 20, 2026. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan, designed to prevent accusations of insider trading. Following the sale, Boughton still holds 299,368 shares in the telehealth company, with the filing providing transparency for investors.
Hims & Hers (NYSE: HIMS) CFO option exercises and pre-planned share sale
Hims & Hers Health CFO Oluyemi Okupe exercised stock options for 12,553 shares and subsequently sold 19,645 Class A Common Stock shares at an average price of $29.9626 under a pre-arranged Rule 10b5-1 trading plan. These transactions took place on April 20, 2026. Following these transactions, Okupe directly held 262,954 shares and indirectly held an additional 7,853 shares.
Hims & Hers chief legal officer Soleil Boughton sells $283,890 in stock
Hims & Hers Health, Inc.'s Chief Legal Officer, Soleil Boughton, sold 9,463 shares of Class A Common Stock for $283,890 on April 20, 2026, under a pre-arranged trading plan. This transaction occurred amidst competitive pressures from Amazon's launch of a weight management program and positive analyst outlooks following potential FDA rule changes regarding peptides, influencing the company's stock performance.
Hims & Hers (HIMS) legal chief sells 9,463 shares in planned trade
Soleil Boughton, Chief Legal Officer of Hims & Hers Health, Inc. (HIMS), sold 9,463 shares of Class A Common Stock for $30.00 each through a pre-arranged Rule 10b5-1 trading plan. Following the transaction, Boughton directly holds 299,368 shares. The sale amounted to $283,890 and was reported on a Form 4 SEC filing.
Hims & Hers CFO Oluyemi Okupe sells $588,615 in Hims stock
Oluyemi Okupe, the Chief Financial Officer of Hims & Hers Health, Inc. (NASDAQ: HIMS), sold 19,645 shares of the company's Class A Common Stock for $588,615 on April 20, 2026. This transaction was part of a pre-arranged trading plan, and on the same day, Okupe also acquired 12,553 shares through stock option exercises. The company has recently faced increased competition in weight management from Amazon, but also saw an uptick in shares following discussions around FDA's removal of certain peptide restrictions.
Hims & Hers vs. Amwell: Which Telehealth Stock Is the Better Buy?
The article compares two prominent telehealth stocks, Hims & Hers and Amwell, to determine which offers a better investment opportunity. It likely delves into their respective business models, financial performance, growth prospects, and competitive advantages to help investors make an informed decision.
Hims & Hers (HIMS) CFO sells 54,927 shares under 10b5-1 plan
Hims & Hers Health, Inc. CFO Oluyemi Okupe reported the sale of 54,927 shares of Class A Common Stock and the exercise of options for 6,184 shares. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan. Following these sales and exercises, Okupe holds 270,046 direct shares and 7,853 indirect shares, with 129,403 stock options remaining.
Hims & Hers CFO Okupe Oluyemi sells $1.46 million in company stock
Hims & Hers Health, Inc. CFO Okupe Oluyemi recently sold approximately $1.46 million worth of company stock across two transactions in mid-April through a Rule 10b5-1 trading plan. Despite the sales, Oluyemi also acquired shares through exercising stock options. The company is facing market changes, including upcoming FDA discussions on injectable peptides that could open new growth avenues, increased competition from Amazon Pharmacy in the weight management sector, and adjusted price targets from analysts like Leerink Partners and BofA Securities.
HIMS (HIMS) insider sale notice: 4,651 and 4,812 Class A shares listed
Hims & Hers Health, Inc. (HIMS) has filed a Form 144 indicating proposed sales of two blocks of Class A shares, totaling 4,651 and 4,812 shares, associated with restricted stock vesting in December 2025 and March 2026, respectively. The filing also reports prior sales of the same amounts in February and March 2026, generating proceeds of $70,741.71 and $118,808.28. These transactions are a result of compensation agreements, specifically restricted stock vesting.
Allbirds, Hims & Hers, Microsoft, Xanadu Quantum And Tesla: Why These 5 Stocks Are On Investors' Radars Today
Major U.S. indices had a mixed day, with the Dow Jones Industrial Average slipping, and the S&P 500 and Nasdaq seeing gains. Several stocks, including Allbirds, Hims & Hers, Microsoft, Xanadu Quantum Technologies, and Tesla, garnered significant investor attention due to company-specific news and market trends. Allbirds pivoted to AI, Xanadu Quantum benefited from Nvidia's new AI model for quantum computing, and Microsoft capitalized on a risk-on session and AI software developments.
Hims & Hers Health, Inc. Class A Trade Ideas — LS:A2QMYY
This article compiles various trade ideas and analyses for Hims & Hers Health, Inc. (HIMS) stock from TradingView users. Traders offer diverse perspectives ranging from bullish long positions based on strong earnings and technical indicators to bearish short setups due to overbought conditions or potential pullbacks, and even strategies involving selling options. The analyses include technical indicators, target prices, stop-loss levels, and risk-reward ratios.
Hims & Hers (NYSE: HIMS) CEO makes 845,866-share bona fide gift
Hims & Hers Health, Inc. CEO Andrew Dudum reported a bona fide gift of 845,866 shares of Class A Common Stock on April 9, 2026, according to a recent Form 4 filing. The transaction involved two gift entries of 422,933 shares each, with no price paid, indicating estate and family wealth planning rather than market trading. Following these gifts, Dudum directly holds 887,684 shares and maintains indirect holdings through various family and GRAT trusts.
Liquidity Mapping Around (HIMS) Price Events
This article provides a quantitative analysis of Hims & Hers Health Inc. (NASDAQ: HIMS) price events, highlighting a weak sentiment across all time horizons that supports a short bias. It details an exceptional 150.1:1 risk-reward short setup targeting 42.6% downside against 0.3% risk. The analysis includes specific institutional trading strategies for long, breakout, and short positions, along with multi-timeframe signal analysis and support/resistance levels.
Hims & Hers Health (HIMS) Is Down 6.1% After Expanding GLP-1 Access With Novo Nordisk Collaboration
Hims & Hers Health (HIMS) shares were down 6.1% following its announcement of expanded GLP-1 access through a collaboration with Novo Nordisk. This partnership aims to deepen the company's push into medically supervised weight management, offering FDA-approved GLP-1 medications and virtual care. The article discusses how this development influences Hims & Hers' growth narrative but also highlights risks like data security and regulatory scrutiny, particularly after a recent customer service data breach.
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm is investigating Hims & Hers Health, Inc. (HIMS) for potential securities law violations after the FDA announced steps to restrict GLP-1 active pharmaceutical ingredients used in non-FDA-approved compounded drugs. This news, compounded by a lawsuit from Novo Nordisk to stop the sale of compounded weight loss drugs, led to a more than 17.8% drop in Hims & Hers shares on February 9, 2026. Investors who suffered losses are encouraged to contact the Schall Law Firm.
Hims (HIMS) CFO exercises options, sells 3,975 shares under plan
Hims & Hers Health, Inc. CFO Oluyemi Okupe exercised stock options for 3,975 shares at $5.01 per share and subsequently sold all 3,975 shares at an average price of $19.977 each. These transactions were performed under a pre-arranged Rule 10b5-1 trading plan. Following these sales, Okupe directly holds 318,789 shares and indirectly holds 7,853 shares through a trust.
Okupe, Hims & Hers health CFO, sells $79k in shares
Oluyemi Okupe, CFO of Hims & Hers Health, Inc., sold 3,975 shares of Class A Common Stock for approximately $79,408 on April 6, 2026, and simultaneously exercised options to acquire the same number of shares. Following these transactions, Okupe directly and indirectly owns a significant number of shares. This insider trade occurred while Hims & Hers Health announced a new partnership with Novo Nordisk to offer GLP-1 medications, contributing to a notable rally in the company's stock.
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm is investigating Hims & Hers Health, Inc. (NYSE: HIMS) for potential securities law violations after the FDA announced intentions to restrict GLP-1 active pharmaceutical ingredients used in non-FDA approved compounded drugs, mass-marketed by Hims & Hers and others. Additionally, Novo Nordisk has filed a lawsuit to bar the company from selling compounded weight loss drugs. This news led to a more than 17.8% drop in Hims & Hers shares on February 9, 2026.
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm has announced an investigation into Hims & Hers Health, Inc. (NYSE: HIMS) for potential securities law violations. This comes after the FDA declared its intent to restrict GLP-1 active pharmaceutical ingredients used in non-FDA-approved compounded drugs, and a lawsuit filed by Novo Nordisk against Hims & Hers regarding compounded weight loss drugs. Following this news, Hims & Hers shares dropped over 17.8%, and the firm is encouraging affected shareholders to participate in the investigation.
Hims & Hers Health (HIMS) Valuation Check As Novo Nordisk GLP 1 Partnership Reopens Growth Path
Hims & Hers Health (HIMS) has resumed its partnership with Novo Nordisk, reintroducing FDA-approved GLP-1 drugs for weight loss, including Wegovy and Ozempic, along with a new subscription program. Despite a recent share price decline, analysts view HIMS as significantly undervalued, with a fair value of $86.09 compared to its current price of $20.33, driven by anticipated revenue expansion and profitability. The article suggests this renewed GLP-1 offering could reopen a growth path for the company, although risks like regulation and future drug maker partnerships remain.
Okupe, Hims & Hers health CFO, sells $79k in shares By Investing.com
Oluyemi Okupe, CFO of Hims & Hers Health, Inc. (NASDAQ:HIMS), recently sold 3,975 Class A Common Stock shares for about $79,408 and simultaneously exercised options to acquire the same number of shares. These transactions were part of a pre-arranged trading plan, and Okupe continues to hold a significant number of shares. This insider activity comes as Hims & Hers Health announced a partnership with Novo Nordisk to offer GLP-1 medications and is experiencing a notable rally in its stock.
Hims & Hers Health Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Hims & Hers Health, Inc. - HIMS
Kahn Swick & Foti, LLC (KSF) has launched an investigation into Hims & Hers Health, Inc. (HIMS) and its officers and directors following a securities class action lawsuit. This investigation stems from Novo Nordisk terminating its partnership with Hims & Hers, alleging the company failed to adhere to laws regarding mass sales of compounded drugs and disseminated deceptive marketing. A court has denied Hims & Hers' motion to dismiss the lawsuit, allowing the case to proceed.
Hims & Hers Health Faces Investor Lawsuit Over Alleged Misconduct
Hims & Hers Health Inc. is facing an investor lawsuit and investigation by Kahn Swick & Foti, LLC, following allegations that the company failed to disclose material information and made misrepresentations about its operations. This legal action stems from Novo Nordisk terminating its partnership with Hims & Hers due to the latter's alleged failure to adhere to laws regarding compounded drugs and deceptive marketing. The ongoing case raises significant concerns about transparency and ethical practices within the digital health industry.
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm is investigating Hims & Hers Health, Inc. (NYSE: HIMS) for potential securities law violations after the FDA announced intentions to restrict GLP-1 active pharmaceutical ingredients used in non-FDA-approved compounded drugs. Additionally, the company faces a lawsuit from Novo Nordisk for selling compounded weight loss drugs, which led to a significant drop in Hims & Hers' stock price. Investors who suffered losses are encouraged to contact the Schall Law Firm.
Did Hims & Hers' Novo Nordisk GLP-1 Partnership Just Shift Hims & Hers Health's (HIMS) Investment Narrative?
Hims & Hers Health announced a partnership with Novo Nordisk to offer FDA-approved GLP-1 medications, including Wegovy, alongside a new weight loss membership to eligible customers. This collaboration aims to expand Hims & Hers' presence in the medical weight management category and deepen customer engagement through its telehealth platform. While this partnership presents a significant opportunity for recurring revenue, it also highlights the risk of heavy reliance on GLP-1s and potential regulatory shifts in this highly visible market.
Hims Novo Nordisk GLP-1 Launch Ties Growth Story To Valuation Gap
Hims & Hers Health has launched access to Novo Nordisk's FDA-approved GLP-1 medications and a new weight loss membership, strengthening its ties to the fast-growing weight loss therapy market. This move could significantly impact the company's user growth, margins, and market differentiation, and investors are watching how it affects Hims' valuation, which Simply Wall St suggests is significantly below estimated fair value. The initiative introduces recurring revenue potential but also increased stock volatility.
Assessing Hims & Hers Health (HIMS) Valuation After A Sharp Pullback And Long Term Shareholder Gains
Hims & Hers Health (HIMS) has experienced a mixed performance, with a recent pullback despite a strong multi-year run, and is currently trading at a significant discount to its intrinsic value and analyst price targets. One bullish narrative suggests a fair value of $86.09, based on fast revenue growth, rising profitability, and a premium earnings multiple. However, this outlook faces risks from potential regulatory scrutiny and increased competition.
Why (HIMS) Price Action Is Critical for Tactical Trading
This article analyzes Hims & Hers Health Inc. Class A (NASDAQ: HIMS), highlighting that near-term weak sentiment may challenge mid-term strength within a broader long-term weak bias. It identifies a mid-channel oscillation pattern and an exceptional 242.6:1 risk-reward setup targeting a 73.5% gain versus 0.3% risk. The article provides institutional trading strategies, including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
